Nutritional supplement ONCOXIN to maintain appetite, body mass and quality of life in patients with advanced cancer on chemotherapy

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Palliative Care
Presenter Mikhail Kopp
Citation Annals of Oncology (2018) 29 (suppl_9): ix129-ix138. 10.1093/annonc/mdy444
Authors M. Kopp1, I. Koroleva2, E. Bilan3, E. Sanz4, F. Petrovskiy5
  • 1Oncology, Medical University Reavitz, 443000 - Samara/RU
  • 2Oncology, Medical University Reavitz, 410004 - Samara/RU
  • 3Oncology, State Oncology Center, 628012 - Khanty-Mansiysk/RU
  • 4Catalysis Scientific Department, Catalysis S.L., 18016 - Madrid/ES
  • 5Clinical Pharmacology, Khanty-Mansiysk State Medical Academy, 628012 - Khanty-Mansiysk/RU



Chemotherapy is associated with decreased appetite, body mass and quality of life in cancer patients. These consequences often require reduction or suspension of chemotherapy thereby affecting relative dose intensity which may worsen prognosis. The present study was intended to evaluate the efficacy of nutritional supplement ONCOXIN (ONCX), which contains microelements, vitamins, amino acids and certain biologically active substances of natural origin, in patients with advanced cancer who receive chemotherapy.


Thirty patients were enrolled in the 20day study (males and females with advanced inoperable gastric/non-SC lung cancer, aged 50 - 80, receiving the 2nd or further course of chemotherapy, BMI ≥ 15, albumin ≥ 25 g/l); 20 were in ONCX group and 10 were controls. In addition to their current treatment, patients from ONCX group used nutritional supplement ONCX 25 ml twice daily for 20 days.


Mean change from baseline in albumin level was +5.6% in ONCX group vs -2.9% in controls (p < 0.05). There were no statistically significant changes in absolute body mass although positive trend was noted for ONCX group and negative for controls. ESAS total score, appetite domain, sums of physical and emotional symptoms were in favor of ONCX group. At the end of the treatment the mean change from baseline in ESAS total score was +9 in control group in contrast to -5.5 for ONCX group (p < 0.05), both changes are greater than minimal clinically important differences of ESAS total score (-3 for improvement and +4 for deterioration).


This is a first pilot study to show the benefits of nutritional supplement ONCOXIN in advanced cancer patients on chemotherapy. We found that ONCOXIN keeps albumin level and improves quality of life in a clinically meaningful manner.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Catalysis S.L.


Catalysis S.L.


E. Sanz: Scientific Department Managing Director: Catalysis S.L.; Manufacturer and provider: ONCOXIN for the purposes of the study. All other authors have declared no conflicts of interest.